

## ASX Announcement

### Race Oncology Investor Webinar Invitation

---

**6 October 2025** – Race Oncology Limited (“Race”) is pleased to invite shareholders and potential investors to attend a special online investor webinar to discuss the recent announcement regarding the company’s discovery of the primary anticancer mechanism of action for (E,E)-bisantrene (RCDS1) (ASX Announcement: 2 October 2025).

During the session, Dr Pete Smith, Executive Chair, and Dr Daniel Tillett, Managing Director and Chief Executive Officer will provide further detail on the discovery and its potential significance for future clinical and commercial plans and will conclude with a Q&A session with investors.

#### Briefing details

**Date:** Wednesday, 8 October, 2025  
**Time:** 6pm-7pm (AEDT)  
**Format:** Online webinar

#### Registration link:

[https://us02web.zoom.us/webinar/register/WN\\_mZs08BT8SDC4V9I2eTLbgA#/registration](https://us02web.zoom.us/webinar/register/WN_mZs08BT8SDC4V9I2eTLbgA#/registration)

Once the registration form is completed, investors will receive a confirmation email detailing how to access the briefing session online.

-ENDS-



## About Race Oncology (ASX: RAC)

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care.

Race's lead asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that functions via G4-DNA and RNA binding with potent inhibition of the key cancer growth regulator MYC. RCDS1 has demonstrated therapeutic activity in cancer patients with a well characterised safety profile.

Race is advancing a proprietary formulation of RCDS1 (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on combinations with an anthracycline (doxorubicin), where we aim to deliver both cardioprotection and enhanced anticancer activity in solid tumour indications. Race is also exploring the use of RC220 as a low intensity treatment for acute myeloid leukaemia and other cancers.

Race Oncology has collaborated with Astex, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong and University of Newcastle, and is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to RC220 for patients with cancer across the world.

Learn more at [www.raceoncology.com](http://www.raceoncology.com).

If you have any questions on this announcement or any past Race Oncology announcements, please go to the Interactive Announcements page in our Investor Hub <https://announcements.raceoncology.com>

*Race encourages all investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at [www.automicgroup.com.au](http://www.automicgroup.com.au).*

**Release authorised by:**

Daniel Tillett, CEO  
info@raceoncology.com

**Media contact:**

Jane Lowe +61 411 117 774  
jane.lowe@irdepartment.com.au

For personal use only